心脏型脂肪酸结合蛋白早期诊断急性心肌梗死的综合效果评价

目的探讨心脏型脂肪酸结合蛋白（H-FABP）在早期诊断急性心肌梗死（AMI）的综合效果。方法选择2011年3月—2013年3月来我院就诊的疑似AMI患者210例,按急诊就诊时间分为0h～3h组和3h～6h组,测定患者血液中的H-FABP、肌钙蛋白（cTnI）、肌酸激酶同工酶（CK-MB）及肌红蛋白（MYO）水平,统计并比较4个心肌标志物的灵敏度、特异性、准确性、阳性预测值及阴性预测值。结果 0h～3h,H-FABP的敏感性、特异性、正确判断率、阳性预测值及阴性预测值分别均相应的高于cTnI、CKMB和MYO（P〈0.05或P〈0.01）。3h～6h,H-FABP的敏感性均高于cTnI、CK-MB和MYO（P〈0.05）,特异性高于MYO（P〈0.05）,阴性预测值均高于cTnI、CK-MB和MYO（P〈0.05）。结论 H-FABP在AMI的早期诊断中,有望取代传统的几种AMI早期诊断标志物。     

血浆心脏型脂肪酸结合蛋白检测在AMI早期诊断中的应用价值

目的 探讨血浆心脏型脂肪酸结合蛋白(H-FABP)检测在急性心肌梗死(AMI)早期诊断中的应用价值.方法 50例疑诊AMI的急性胸痛患者,按最终确诊结果分为AMI组28例、非AMI组22例,按胸痛时间分为＜2h和2～4h两组.50例患者胸痛发作4h内进行血浆H-FABP和肌钙蛋白I(cTnI)、肌红蛋白(MYO)检测,观察H-FABP对AMI早期诊断的敏感性和特异性.结果 胸痛发作≤4 h检测H-FABP、cTnI、MYO诊断AMI的敏感性分别为82.1％、46.4％、57.1％,前者与后两者相比,P均＜0.05;H-FABP、cTnI、MYO诊断AMI的特异性分别为86.4％、90.9％、59.1％,H-FABP诊断AMI的特异性与MYO相比,P＜0.05.胸痛发作＜2h和2～4h者检测H-FABP诊断AMI的敏感性分别为75.0％和91.7％.结论 血浆H-FABP检测在AMI的早期诊断中有重要应用价值,其敏感性高于cTnI、MYO,特异性高于MYO.     

心肌型脂肪酸结合蛋白在急性胸痛患者中的诊断价值

目的研究心肌型脂肪酸结合蛋白(H-FABP)对急性胸痛患者中的诊断价值,比较不同心脏标志物诊断AMI的价值。方法选择2010年10月至2012年6月因急性胸痛发作6h内就诊患者122例,即刻采肘静脉血5ml。采用快速检测试剂盒(胶体金法)检测H-FABP,同时测定肌钙蛋白T(cTnT)和肌酸激酶同工酶MB(CK-MB)。采用SPSS17.0软件比较3种心脏标志物在诊断急性心肌梗死(AMI)的灵敏度、特异度、阳性预测值和阴性预测值。结果在AMI发病6h内,H-FABP对AMI的诊断灵敏度及阴性预测值均高于cTnT和CK-MB,差异有统计学意义(P<0.01)。结论 H-FABP是目前早期(0~6h)诊断AMI比较敏感和准确的心脏生化标志物之一。     

心型脂肪酸结合蛋白与肌钙蛋白Ⅰ联合检测在急性心肌梗死诊断中的临床价值

目的 探讨血清心型脂肪酸结合蛋白（H-FABP）与肌钙蛋白Ⅰ（cTnⅠ）联合检测在急性心肌梗死（AMI）诊断中的临床价值.方法 选取疑似AMI的胸痛患者190例,按胸痛发作时间分为＜3小时、3～6小时、6～12小时3组,检测患者血清H-FABP、肌红蛋白（Myo）、肌酸激酶同工酶（CK-MB）、cTnⅠ,比较4种心肌标志物诊断AMI的敏感度、特异度、阳性预测值和阴性预测值,同时比较不同心肌标志物组合（Myo＋ CK-MB＋ cTnⅠ、cTnⅠ＋ H-FABP）对胸痛发作≤6小时的AMI诊断的准确率.结果 胸痛发作＜3小时组H-FABP诊断AMI敏感度优于与其他指标（P＜0.05）;6～12小时组cTnⅠ敏感度和特异度均优于H-FABP（P ＜0.05）;＜3小时组cTnⅠ＋ H-FABP联合检测诊断AMI的敏感度为85.4％,特异度为90.4％,Myo＋ CK-MB＋ cTnⅠ联合检测诊断AMI的敏感度为65.8％,特异度为85.7％;3～6小时组cTnⅠ＋ H-FABP联合检测诊断AMI的敏感度为94.7％,特异度为90.3％,Myo＋ CK-MB＋ cTnⅠ联合检测诊断AMI的敏感度为81.6％,特异度为83.9％.cTnⅠ＋ H-FABP组合在＜3小时组与3～6小时组的诊断符合率（87.1％、92.8％）均高于Myo＋CK-MB＋ cTnⅠ组合（72.6％、82.6％）.结论 H-FABP在AMI发病早期（3小时内）诊断具有较高的敏感度,中晚期（6～12小时）诊断cTnⅠ敏感度和特异度优于H-FABP.血清H-FABP与cTnⅠ联合检测对诊断AMI具有较高的敏感度和符合率,优于Myo＋ CK-MB＋ cTnⅠ组合.     

比较心肌型脂肪酸结合蛋白在 急性心肌梗死早期诊断中的优势

【摘要】 目的 定量分析心肌型脂肪酸结合蛋白（H-FABP）在急性心肌梗死（AMI）早期诊断中的临床应用价值。方法 选择因胸痛而就诊的患者120例,最后确诊 AMI患者69例,非AMI患者51例为对照组,按胸痛发作距就诊时间分为<3 h、3～6 h和>6 h以上三组。采用免疫比浊法定量测定各组H-FABP的浓度,同时检测肌酸激酶同工酶（CK-MB）和肌钙蛋白I（hs-cTnI）,比较各指标在诊断AMI早期的敏感度和特异度。结果 入院各时间段AMI组H-FABP血液浓度均高于对照组,差异均有统计学意义（P<0.05）;CK-MB和cTnI在3 h内检测结果与对照组比较未见统计学差异（P>0.05）,3～6 h和>6 h两组检测结果与对照组比较差异有统计学意义（P<0.05）。H-FABP的敏感度在发病3 h内和3～6 h分别为74.1%和87.5%,高于CK-MB（18.5%、54.1%)）和cTnI（14.8%、58.3%）,差异有统计学意义（P<0.05）;发病6 h后H-FABP的敏感性为83.3%,低于CK-MB（88.9%）和cTnI（94.4%）,无统计学意义（P>0.05）。各检测指标中特异性最高的是cTnI,但差异均无统计学意义（P>0.05）。结论 H-FABP定量检测在AMI早期诊断中有较高的敏感度,与其他高特异性指标联合检查可提高AMI的早期诊断准确率。     

快速检测血浆心肌脂肪酸结合蛋白诊断老年早期急性心肌梗死

目的 探讨快速检测血浆心肌脂肪酸结合蛋白（H-FABP）诊断老年早期急性心肌梗死（AMI）的价值。方法 采用免疫层析技术研制H-FABP快速检测试剂条，检测64例发病6h内的老年胸痛患者的血浆标本，比较其与心肌肌钙蛋白Ⅰ（cTnⅠ）、肌酸激酶MB同工酶（CK-MB）和肌红蛋白（MYO）诊断早期AMI的敏感性、特异性。结果 快速检测H-FABP诊断AMI的敏感性（90．48％）显著高于cTnⅠ（57．29％）和CK-MB（57．29％）（P=0．016），与MYO（85．71％）比较差异无统计学意义；H-FABP的特异性（95．35％）高于MYO（60．47％）（P=0．014），与cTnⅠ（97．44％）、CK-MB（83．72％）比较差异无统计学意义。结论 快速检测H-FABP对于早期AMI具有较高的敏感性和良好的特异性，可用于老年早期AMI的筛选。     

肌红蛋白和心肌肌钙蛋白I联合快速检测对急性心肌梗死的早期诊断价值

目的探讨两种心肌损伤标志物肌红蛋白(Mb)及心肌肌钙蛋白I(cTn I)联合快速检测定性分析对急性心肌梗死(AMI)的早期诊断价值.方法因胸痛发作发病3 h～6 h,临床疑诊为AMI的病人120例.入院后即刻在床边采集静脉血测定Mb和cTn I,比较Mb、cTn I诊断AMI的敏感性、特异性、准确性、阳性预测值和阴性预测值.结果 Mb的敏感性、阴性预测值均为100.0%,cTn I为94.4%和92.0%,Mb明显高于cTn I(P<0.05或P<0.01);而cTn I的准确性、特异性和阳性预测值分别为95.0%、95.8%和97.1%,Mb为83.3%、58.3%和78.3%,cTn I明显高于Mb(P<0.05或P<0.01);采用Mb联合cTn I检测,其特异性达到100.0%,高于单纯Mb和cTn I检测,有统计学意义(P<0.01).结论 Mb及cTn I快速联合检测有助于早期诊断或排除AMI,方法简便快捷,适合于急诊及院前急救.     

心脏脂肪酸结合蛋白在早期急性心肌梗死诊断中的价值

目的:探讨心脏型脂肪酸结合蛋白(H-FABP)在急性心肌梗死(AMI)诊断中的价值。方法:选取2016年5月至2017年8月,因急性胸痛就诊的患者187例,其中确诊为AMI患者83例(AMI组),非AMI患者104例(非AMI组),入院即刻采血测定心肌肌钙蛋白(cTnI)、肌酸激酶同工酶(CKMB)及H-FABP水平。结果:AMI组患者cTnI、CK-MB水平及H-FABP阳性率分别为5.64(0.43,12.66)μg/L、7.22(5.01,16.55)μg/L和84.34%,明显高于非AMI组(P0.05);H-FABP诊断AMI的灵敏度为84.3%,明显高于cTnI和CK-MB(P0.05),而特异度为79.81%,明显低于cTnI和CK-MB(P0.05);胸痛发作到检测时间6h时,H-FABP诊断AMI的灵敏度为93.33%,明显高于cTnI和CK-MB(P0.05),特异为83.61%,明显低于CK-MB(P0.05),而与cTnI比较,差异无统计学意义(P0.05)。结论:相对于cTnI和CK-MB,H-FABP在早期诊断AMI中有较好的诊断价值,尤其对于胸痛发作到检测时间6h内的患者,其诊断价值较高。     

心肌损伤标记物水平在不同类型冠心病中的观察研究

目的研究不同心肌损伤标记物诊断早期急性心肌梗死(AMI)的意义。方法选择胸痛患者60例,AMI组32例,UAP组18例,SAP组10例,ELISA法测定患者胸痛<3h,3～6h血心型脂肪酸结合蛋白(H-FABP)、单核细胞趋化蛋白1(MCP-1)、凝血酶原片段(F1+2)浓度变化,同时检测肌钙蛋白I(cTnI)和肌红蛋白(MYO)。分析胸痛<3h,≤6hH-FABP、MCP-1、F1+2诊断AMI的敏感性和特异性。结果与AMI组比较,UAP组和SAP组胸痛<3h,3～6h血浆H-FABP、MCP-1、F1+2、cTnI及MYO明显下降(P<0.05,P<0.01);与UAP组比较,SAP组胸痛<3h,3～6h血浆MCP-1、F1+2明显下降(P<0.05)。在胸痛<3h,≤6hH-FABP敏感性高于其他指标;胸痛<3h,≤6hH-FABP特异性均与cTnI相似,高于其他指标。胸痛≤6hF1+2及MCP-1敏感性、特异性较胸痛<3h明显升高,F1+2敏感性与MYO相似,但MCP-1敏感性与MYO相比仍较低。结论 H-FABP在时效方面更早于cTnI,总体诊断价值要优于cTnI,有望成为理想的早期诊断AMI的生化标记物。     

心肌型脂肪酸结合蛋白在急性心肌梗死早期诊断中的价值

急性心肌梗死(AMI)自胸痛发作到再灌注治疗的时间对预后有较大的影响,因而要求发病早期迅速确诊.既往一般多检测心肌肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnI或cTnT)和肌红蛋白(MYO),但CK-MB和cTnI(T)在心肌缺血时出现较晚,缺乏早期诊断AMI的敏感性.心肌细胞心肌型脂肪酸结合蛋白(Heart-type Fatty Acid-binding Protein,H-FABP)含量较骨骼肌高,与MYO相比具有更好的心肌特异性[1].     

床旁快速检测心型脂肪酸结合蛋白在老年急性心肌梗死早期诊断中的价值

目的 采用床旁快速检测（POCT）心型脂肪酸结合蛋白（H-FABP）,探讨心型脂肪酸结合蛋白（H-FABP）、肌钙蛋白T（cTnT）、肌酸激酶同工酶（CK-MB）在急性心肌梗死患者（AMI）早期诊断中的价值.方法 选取因急性胸痛疑似ACS的老年患者,留取血浆并测定血浆H-FABP、cTnT、CK-MB值,根据发病时间分为0～6h、6～12 h和＞12 h组进行分析.结果 在AMI早期（0～6h）H-FABP诊断效率（0.913）高于cTnT（0.786）和CK-MB（0.742）,灵敏度和特异度也较高（78.62％、85.70％）,血浆H-FABP浓度高于不稳定心绞痛（UAP）组和对照组（P＜0.01）.结论 H-FABP在AMI发生的早期有较高的诊断效率、灵敏性和特异性,可以作为早期,特别是6h内诊断AMI的生化标记物.POCT快速检测试剂盒具有操作简便快捷,结果可靠等优点,适合在临床推广.     

The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase–myocardial band

Heart-type fatty acid-binding protein (H-FABP), a new biochemical marker of sarcolemmal injury due to acute myocardial ischemia, can be used as a tool in early diagnosis and management of patients at high risk. The aim of this study was to determine the early diagnostic value of H-FABP in acute coronary syndrome (within 6–24 h of chest pain) and to compare it with troponin-T (TnT) and creatine kinase–myocardial band (CK-MB) for accuracy. The study consisted of 40 consecutive patients with chest pain admitted to the coronary care unit with the diagnosis of suspected acute coronary syndrome. The patient population consisted of two groups according to the time of admission; the first group (26 patients) included patients admitted within 6 h of chest pain, and the second group (14 patients) included patients admitted within 6–24 h of chest pain. The blood samples for H-FABP, TnT, and CK-MB were obtained at admittance, at the 6th, and at the 24th hours for the first group, and at admittance and at the 24th hours for the second. Statistical analysis was performed among the 26 patients for the first 6 h values, and among all 40 patients for the values obtained within 6–24 h and at the 24th hour. The patients were then divided into groups according to the changes in the electrocardiogram (ECG) and cardiac enzymes as unstable angina pectoris, non-ST elevation myocardial infarction (MI), and ST-elevation MI. Coronary angiography was performed in 38 (95%) patients. Sensitivity of TnT, CK-MB, and H-FABP in the first group (within 6 h of chest pain) were 38%, 76%, and 95% respectively. The sensitivity of H-FABP was significantly higher than TnT (P = 0.014). Sensitivity of TnT, CK-MB, and H-FABP tests in the second time period (within 6–24 h of chest pain) were 100%, 90%, and 91% respectively. In this time period, the sensitivity of TnT was higher than H-FABP, but it was statistically insignificant. At the 24th hour, sensitivity of TnT was 100%, CK-MB 90%, and H-FABP 27.3%, and TnT and CK-MB were more sensitive than H-FABP for the whole group (P = 0.002). In the first group (within 6 h of chest pain) H-FABP positivity was slightly but insignificantly higher in patients with two- and three-vessel disease compared with those with one-vessel disease (60.7% and 33.3%, P = 0.19) and in the same group, patients who underwent primary coronary intervention had a significantly higher H-FABP positivity than others (80%, 32%, P = 0.02). Within 6–24 h of chest pain, H-FABP positivity was 80% in patients with one-vessel disease and 71.4% in patients with two- and three-vessel disease (P = 0.69). Within 6–24 h, positivity of H-FABP reached a peak value of 100% in patients who underwent primary coronary intervention, while H-FABP was positive in 60% of the others (P < 0.001). We conclude that within the 6 h of acute coronary syndrome, H-FABP seems to be a more sensitive biochemical marker than TnT in the early detection of ischemic myocardial necrosis. But after the first 6 h of the onset of chest pain the sensitivity of H-FABP decreases, and this marker should not be used alone in patients admitted 24 h after the onset of chest pain.     

心肌脂肪酸结合蛋白对早期急性心肌梗死的诊断

目的研究血浆心肌脂肪酸结合蛋白(HFABP)在早期急性心肌梗死(AMI)诊断中的价值。方法选择93例发病6h内的胸痛患者,其中AMI组32例,非AMI组61例[含不稳定型心绞痛(UAP)24例,稳定型心绞痛(SAP)者22例,非心源性胸痛者15例];正常对照组选择69例正常人。采用双抗体夹心酶联免疫一步法检测正常人和患者发病0～3h或3～6h血浆的HFABP含量,并与心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CKMB)和肌红蛋白(MYO)的检测结果进行比较,分析4种生化标志物诊断发病3h内和6h内AMI的敏感性、特异性和准确性。结果在0～3h、0～6h时间段,HFABP诊断AMI的敏感性(64.29%、84.38%)显著高于cTnI(28.57%、53.13%)和CKMB(21.43%、56.25%),与MYO(71.43%、78.13%)比较差异无统计学意义;在诊断特异性上,4种生化标志物差异无统计学意义;在诊断准确性上,HFABP的ROC曲线下面积(0.979、0.958)显著高于cTnI(0.800、0.878)、CKMB(0.575、0.782)和MYO(0.796、0.882)。结论HFABP对于诊断早期AMI具有较高的敏感性和良好的特异性,其诊断准确性优于cTnI、CKMB、MYO。     

Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain

Background

Heart-type fatty acid-binding protein (H-FABP) is an emerging biomarker, which was found to be sensitive for the early diagnosis of acute myocardial infarction (AMI). We prospectively investigated the usefulness of H-FABP determination for the evaluation of acute chest pain in patients arriving at the emergency department.

Methods

Fifty-four patients presenting with acute ischemic chest pain were evaluated. H-FABP was estimated at admission using latex-enhanced immunoturbidimetric assay. Serial cardiac troponin I (cTnI), creatinine kinase-MB (CK-MB) determination, ischemia workup with stress testing, and/or coronary angiogram (CAG) were performed according to standard protocols.

Results

The sensitivity and specificity of H-FABP was 89.7% and 68%, for cTnI it was 62.1% and 100%, and for CK-MB it was 44.8% and 92%, respectively for diagnosis of AMI. The sensitivity of H-FABP was found to be far superior to initial cTnI and CK-MB, for those seen within 6 h (100% vs. 46.1%, 33% respectively). On further evaluation of patients with positive H-FABP and negative cTnI, 71.4% of the patients had significant lesion on CAG, indicating ischemic cause of H-FABP elevation. Six patients with normal cTnI and CK-MB with high H-FABP had ST elevation on subsequent ECGs and were taken for primary angioplasty.

Conclusion

H-FABP is a highly sensitive biomarker for the early diagnosis of AMI. H-FABP as early marker and cTnI as late marker would be the ideal combination to cover the complete diagnostic window for AMI. Detection of myocardial injury by H-FABP may also be applied in patients with unstable angina. H-FABP can also be used as a marker for early detection of STEMI before the ECG changes become apparent.     

心肌型脂肪酸结合蛋白(H-FABP)与cTnI、CK-MB组合在诊断早期AMI中的比较

目的研究血清心肌型脂肪酸结合蛋白（H—FABP）在早期急性心肌梗死（AMI）诊断中的价值,比较不同心肌损伤标志物组合诊断早期AMI的价值。方法选择疑似急性冠脉综合征患者102例,采用酶联免疫吸附法（Elisa）测定AMI患者发病1h、2h、3h、4～6h、7～12h时血清H—FABP浓度变化,并与心肌肌钙蛋白I（cTnI）、肌酸激酶同工酶（CK—MB）的检测结果进行比较,分析3种心肌损伤标志物及不同心肌标志物组合H—FABP＋cTnI与H—FABP＋CK—MB在诊断不同发病时间段AMI的敏感性和特异性。结果①在AMI发病3h内,H—FABP的诊断敏感性（66．7％）优于cTnI（0％）和CK—MB（0％）,差异有统计学意义（P〈0．05）。在AMI发病4～6h内,H—FABP的敏感性（94．4％）仍高于cTnI（61．1％）和CK—MB（50％）,差异有统计学意义（P〈0．05）。②H—FABP＋cTnI组合对AMI的诊断敏感度最高（95．8％）,特异度亦最高（100％）。H-FABP＋cTnI组合次之,分别为93．75％和97．2％。这两种组合对AMI的诊断敏感度与单个H—FABP、cTnI和CK—MB比较,差异有统计学意义（P〈0．05）,诊断特异度亦明显升高。结论在AMI发病6h内,H—FABP是最为敏感的心脏标志物,尤以发病3h内最敏感。H—FABP与不同心肌损伤标志物cTnI和CK—MB的组合均具有较高的敏感性和特异性,可提高早期诊断AMI的准确率。     

Diagnostic and prognostic value of heart-type fatty acid-binding protein (H-FABP), an early biochemical marker of myocardial injury

Heart-type fatty acid-binding protein (H-FABP) is a 132 amino acids soluble protein, with general characteristics resembling myoglobin. Because of its low molecular weight (15 kd) and cytoplasmic location, it constitutes a biologic marker readily released into the circulation after myocardial injury. Despite the development of various immunoassays to measure H-FABP, few are currently easy to perform, quantitative and applicable in emergency. Most studies have shown the diagnostic sensitivity of H-FABP (i.e. its ability to detect the presence of a myocardial infarction) to be high, above that of myoglobin in patients presenting within 3 to 6 h of after the onset of chest pain. This superiority is attributable to an earlier and more rapid rise in H-FABP than in myoglobin. After thrombolysis, the serum concentrations of H-FABP peak at approximately 4 h after the onset of chest pain, and return to normal values within 24 h. Because of this rapid return of its blood concentration to baseline, H-FABP can contribute to an early biologic diagnosis of post-thrombolysis reperfusion and re-infarction. In absence of renal insufficiency, H-FABP also provides a reliable estimate of infarct size associated with ST segment elevation. When myocardial injury occurs after cardiac surgery, the second peak in H-FABP concentration precedes that of myoglobin, CK-MB or troponins. In addition, H-FABP peaks earlier and is more sensitive than troponins in the detection of subtle myocardial injury in patients presenting with acute coronary syndrome without ST segment elevation, and in patients with severe heart failure, thus offering early prognostic information. Limitations of H-FABP include a limited cardio-specificity, a narrow diagnostic window (20 to 30 h), and a nearly exclusive renal elimination.     

Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room.

BACKGROUND: Measurement of circulating biomarkers has enabled early diagnosis and risk assessment of acute coronary syndrome. This study sought diagnostic values of the first single-point data of biomarkers obtained soon after patient arrival by comparing with scintigraphically quantified myocardial injury in patients presenting with acute chest pain at an emergency room. METHODS AND RESULTS: Serial blood samples were taken soon after arrival in an emergency department in 74 patients with suspected acute coronary syndrome to quantify blood levels of troponin-T (TnT), heart-type fatty acid-binding protein (H-FABP), myocardial-bound creatine kinase (CK-MB), and myoglobin. Myocardial perfusion and metabolic defects were scintigraphically quantified. The first single-point data had high positive predictive values for detecting the defects (80-100%) but low negative predictive values (15-41%). CK-MB and TnT had higher specificities (73-100%) but significantly lower positive rates (22-27%) than the others (61-68%), resulting in greater sensitivities of H-FABP and myoglobin (75-80%) than those of CK-MB and TnT (29-35%). Among biomarkers, TnT peak concentrations most closely correlated with scintigraphic abnormalities. CONCLUSION: H-FABP can contribute to early detection of myocardial injury and TnT is most likely to correlate with injured myocardial mass. The differential features of biomarkers are complementary in patients with acute chest pain presenting at an emergency room.     

Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome

Although heart-type fatty acid-binding protein (H-FABP) can be a marker of sarcolemmal injury due to acute myocardial ischemia, the diagnostic or prognostic value is not established in patients with acute chest pain. This multicenter prospective study aimed to determine the diagnostic and prognostic values of H-FABP in 133 patients presenting to an emergency room with suspected acute coronary syndrome (ACS) by comparing with those of conventional biomarkers. H-FABP and myoglobin had greater positive results than did creatine kinase-MB or troponin T. Receiver operating characteristics analysis revealed that H-FABP was the most reliable for detection of ACS and that H-FABP had the greatest sensitivities for identification of patients requiring emergency hospitalization, coronary angiography, and interventional therapy within 7 days among the biomarkers. Thus, H-FABP can be an early diagnostic and prognostic biochemical marker, particularly within the first 6 h from the onset of chest symptoms, in patients with chest pain at an emergency department.     

Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitivity troponin T in emergency room patients presenting with chest pain

BACKGROUND: The aim of the present study was to evaluate the diagnostic accuracy of high-sensitivity troponin T (hsTnT) in patients with suspected acute coronary syndrome (ACS) in comparison to heart fatty acid-binding protein (H-FABP), high-sensitivity C-reactive protein, myeloperoxidase (MPO), and pentraxin 3 (PTX3). METHODS AND REsults: Patients (n=432) with chest pain were recruited for the analysis. ACS was diagnosed in 298 patients (69%). The diagnostic accuracy of measurements obtained at presentation, as quantified by the area under the receiver operating curve (AUC), was highest for hsTnT (AUC=0.82; 95% confidence interval [CI]: 0.78-0.87) and H-FABP (AUC=0.83; 95%CI: 0.78-0.87). Sensitivity (87.9%) and negative likelihood (LH; 0.2) for hsTnT were the highest and lowest, respectively, but H-FABP had the highest specificity (78.5%) and positive LH (3.6). Among patients who presented within 2h after the onset of chest pain, MPO had the highest AUC (0.82; 95%CI: 0.69-0.94). Combined use of H-FABP and MPO measurements yielded a sensitivity of 69.2%, specificity of 84.2%, positive LH of 4.4, and negative LH of 0.4. CONCLUSIONS: The hsTnT assay offers excellent diagnostic performance to rule out ACS, but it is prone to false-positive results. H-FABP offers similar overall diagnostic performance, while the combination of H-FABP and MPO assays may improve the diagnosis of ACS, particularly in patients with recent onset of chest pain.     

急性心肌梗死患者血浆心型脂肪酸结合蛋白的动态变化及意义

目的 探讨急性心肌梗死（AMI）患者心型脂肪酸结合蛋白（H-FABP）的动态变化和临床意义.方法 采用固相夹心酶联免疫法（ELISA）测定50例AMI患者发病后6 h以内（PCI术前）,发病后9 h、12 h、24 h、48 h血浆H-FABP、肌红蛋白（MYO）、肌钙蛋白I（cTnI）、肌酸激酶同工酶（CK-MB）浓度.将AMI患者分为死亡组、并发症组和无并发症组进行对比分析.结果 AMI患者血浆H-FABP浓度为（35.13±5.72）μg/L,明显高于对照组的（5.16±1.43）μg/L,差异有统计学意义（P＜0.01）.3个亚组中无并发症组患者血浆H-FABP浓度在发病后4～6 h达高峰,12～24 h恢复到正常范围;而并发症组和死亡组患者血浆H-FABP浓度在各个时间点都高于无并发症组,而且峰值延迟、持续不降并有增高趋势.三组的组间、不同时间点,以及组间和不同时间点的交互作用差异均有统计学意义（P＜0.05）.结论 H-FABP是AMI早期诊断的特异性生化标记物,对AMI有重要的诊断价值.AMI患者血浆H-FABP峰值延长甚至持续升高可能与心肌梗死后各种并发症对心肌细胞的持续损伤有关,H-FABP浓度的动态变化对AMI患者危险分层有一定的预测价值.